Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies.

Stephanie J Loomis Ryan MillerCarmen Castrillo-VigueraKimberly Umans Wenting Cheng John O'Gorman Richard Hughes Samantha Budd HaeberleinChristopher D Whelan

Published in: Neurology (2023)

Both trials (ENGAGE [221AD301]: NCT02477800 and EMERGE [221AD302]: NCT02484547) were registered in June 2015 at clinicaltrials.gov and enrolled patients from August 2015 to July 2018.

Keyphrases

end stage renal disease
genome wide association
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
case control
patient reported outcomes